ES2084940T3 - Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas. - Google Patents

Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas.

Info

Publication number
ES2084940T3
ES2084940T3 ES92305287T ES92305287T ES2084940T3 ES 2084940 T3 ES2084940 T3 ES 2084940T3 ES 92305287 T ES92305287 T ES 92305287T ES 92305287 T ES92305287 T ES 92305287T ES 2084940 T3 ES2084940 T3 ES 2084940T3
Authority
ES
Spain
Prior art keywords
lymphoma
rapamicine
treatment
adult leukemia
atl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92305287T
Other languages
English (en)
Inventor
Glenn Alvin Miller
Mark Barry Rabin
William Joseph Jnr Harrington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2084940T3 publication Critical patent/ES2084940T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

ESTE INVENTO PROPORCIONA UN METODO PARA TRATAR CELULAS T ADULTAS DE LEUCEMIA/LINFOMA (ATL) EN UN MAMIFERO QUE LO NECESITE QUE COMPRENDE LA ADMINISTACION DE UNA CANTIDAD ANTIPROLIFERATIVA DE RAPAMICIN Y ES PARTICULARMENTE UTIL EN ATAJAR O HACER REMITIR ATL.
ES92305287T 1991-06-18 1992-06-09 Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas. Expired - Lifetime ES2084940T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71777391A 1991-06-18 1991-06-18

Publications (1)

Publication Number Publication Date
ES2084940T3 true ES2084940T3 (es) 1996-05-16

Family

ID=24883429

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92305287T Expired - Lifetime ES2084940T3 (es) 1991-06-18 1992-06-09 Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas.

Country Status (20)

Country Link
EP (1) EP0525960B1 (es)
JP (1) JP2562548B2 (es)
KR (1) KR930000115A (es)
AT (1) ATE135583T1 (es)
AU (1) AU651698B2 (es)
CA (1) CA2071456A1 (es)
CZ (1) CZ281663B6 (es)
DE (1) DE69209183T2 (es)
DK (1) DK0525960T3 (es)
ES (1) ES2084940T3 (es)
GR (1) GR3019749T3 (es)
HK (1) HK108897A (es)
HU (1) HU214326B (es)
IE (1) IE71646B1 (es)
IL (1) IL102185A (es)
MX (1) MX9202939A (es)
NZ (1) NZ243175A (es)
SG (1) SG43072A1 (es)
SK (1) SK279804B6 (es)
ZA (1) ZA924369B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
ES2176245T3 (es) 1993-04-23 2002-12-01 Wyeth Corp Anticuerpos de ramapicinas de ciclo abierto.
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
EP0729471A1 (en) * 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
CA2270373A1 (en) * 1996-10-31 1998-05-07 American Home Products Corporation Synergistic composition comprising rapamycin and calcitriol
BR9713661A (pt) 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
RU2184541C2 (ru) * 1997-06-13 2002-07-10 Американ Хоум Продактс Корпорейшн Препараты рапамицина для орального применения
AU2494499A (en) * 1998-02-04 1999-08-23 Applied Genetics Incorporated Dermatics Compositions and methods for modulating cytokine release in response to genotoxic agents
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
EP2298299A3 (en) * 2000-01-14 2012-02-29 The Trustees Of The University Of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
ES2313983T3 (es) 2000-09-19 2009-03-16 Wyeth Esteres hidrosolubles de rapamicina.
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
IL158800A0 (en) * 2001-06-01 2004-05-12 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
MXPA04001523A (es) 2001-08-22 2004-05-31 Wyeth Corp Dialdehidos de rapamicina.
DE60206512T2 (de) 2001-08-22 2006-06-22 Wyeth Rapamycin 29-enole
AU2003247483A1 (en) * 2002-05-30 2003-12-31 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
PT1553940E (pt) 2002-07-30 2008-05-09 Wyeth Corp Formulações parentéricas contendo um hidroxi-éster de rapamicina
AR042938A1 (es) 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US7445916B2 (en) 2004-04-14 2008-11-04 Wyeth Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
PL1761540T3 (pl) 2004-05-13 2017-06-30 Icos Corporation Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
JP2008500338A (ja) * 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
AU2006315512B2 (en) 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
EP2702993B1 (en) 2006-09-13 2017-12-06 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
NZ631024A (en) 2008-11-13 2016-04-29 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
SG174529A1 (en) 2009-03-24 2011-10-28 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
ES2685947T3 (es) 2009-04-10 2018-10-15 Haiyan Qi Agentes antienvejecimiento
PT2421536E (pt) 2009-04-20 2015-10-20 Gilead Calistoga Llc Métodos de tratamento para tumores sólidos
EP2456443A1 (en) 2009-07-21 2012-05-30 Gilead Calistoga LLC Treatment of liver disorders with pi3k inhibitors
BR112014014181A2 (pt) 2011-12-16 2017-06-13 Oncology Inst Of Southern Switzerland combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer
AP2014007875A0 (en) 2012-03-05 2014-08-31 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
PT3083630T (pt) 2013-12-20 2019-11-15 Gilead Calistoga Llc Procedimentos para inibidores da fosfatidilinositol 3-quinase
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
JP2020507632A (ja) 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. ラパマイシン類似体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
GB8610114D0 (en) * 1986-04-25 1986-05-29 Esselte Letraset Ltd Sign-making materials

Also Published As

Publication number Publication date
SG43072A1 (en) 1997-10-17
HU214326B (hu) 1998-03-02
HUT61480A (en) 1993-01-28
JP2562548B2 (ja) 1996-12-11
ATE135583T1 (de) 1996-04-15
KR930000115A (ko) 1993-01-15
SK279804B6 (sk) 1999-04-13
AU1825592A (en) 1992-12-24
CZ182492A3 (en) 1993-12-15
IE71646B1 (en) 1997-02-26
EP0525960A1 (en) 1993-02-03
CZ281663B6 (cs) 1996-12-11
HU9202023D0 (en) 1992-09-28
NZ243175A (en) 1997-06-24
CA2071456A1 (en) 1992-12-19
HK108897A (en) 1997-08-22
IE921957A1 (en) 1992-12-30
SK182492A3 (en) 1994-10-05
GR3019749T3 (en) 1996-07-31
AU651698B2 (en) 1994-07-28
DE69209183T2 (de) 1996-08-08
JPH05170771A (ja) 1993-07-09
EP0525960B1 (en) 1996-03-20
IL102185A (en) 1997-09-30
MX9202939A (es) 1994-05-31
ZA924369B (en) 1993-12-15
DK0525960T3 (da) 1996-04-15
DE69209183D1 (de) 1996-04-25

Similar Documents

Publication Publication Date Title
ES2084940T3 (es) Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas.
DE69127437D1 (de) Stickoxide zur gewichtsreduktion
DE3882899D1 (de) Mehrschicht-kollimator und diesen verwendende vorrichtung.
FI910075A0 (fi) Avlaegsnande av ytfoeroreningar genom bestraolning med en hoegenergikaella.
DK0414289T3 (da) Spirocykliske, antipsykotiske midler
DE69213232D1 (de) Fallschutzgerat
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ES2089723T3 (es) 29-demetoxirapamicina para inducir la inmunodepresion.
ATE258068T1 (de) Zusammensetzung, vorrichtung und verfahren zur verbesserten elektrotransport-wirkstoffabgabe
FI870506A0 (fi) Saollningsanlaeggning med sammanbygd foerdelnings- och avskiljningsanordning.
DK0458590T3 (da) Behandling af okulær hypertension med en synergistisk konbination
PT656209E (pt) Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao
FI940519A0 (fi) Interleukiini-10-analogien tai -antagonistien käyttö endotoksiinin taisuperantigeenin indusoiman toksisuuden hoitamiseksi
IT1226084B (it) Dispositivo di tensionamento cinghia per stampante seriale.
DE69106973D1 (de) Sicherheitsgurtstrammer.
ATE242663T1 (de) Vorrichtung zur vermessung und sortierung von werkstücken
ATE83907T1 (de) Vorrichtung zum offenhalten eines ureterotomieschnitts.
ITTO920702A0 (it) Apparecchio per vulcanizzare cinghie di gomma senza fine
ATE160756T1 (de) Förderbandsystem und heizapparat in dem das system anwendung findet
ATE73063T1 (de) Vorrichtung zum versetzen und festhalten eines fahrzeugsicherheitsgurtes mit aufrollvorrichtung in eine entspannte position.
DE69208404D1 (de) Vorrichtung zur Unterdrückung von Riemengeräuschen und -schwingungen
ES1013657Y (es) Aparato de gimnasia por poleas.
SU611820A1 (ru) Устройство дл поддержани ленты конвейера с места ее загрузки
KR910002507U (ko) 자동차용 시트 벨트(Seat belt)
IT219006Z2 (it) Dispositivo per la facile applicazione su cintura, in particolare per subaqueo, di pesi o zavorre

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 525960

Country of ref document: ES